Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs
03:48pm, Monday, 16'th May 2022
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now
10:30am, Saturday, 14'th May 2022 The Motley Fool
The company's current treatments dominate the cystic fibrosis market, but it's the pipeline that makes this stock so intriguing.
Why Editas Medicine's Shares Fell 28.9% This Week
03:52pm, Friday, 13'th May 2022 The Motley Fool
The company's progress for its lead therapy has been slow.
2 Stocks With 75% to 183% Upside, According to Wall Street
03:45pm, Friday, 13'th May 2022 The Motley Fool
These two companies have been southbound lately.
These 5-Stock Samplers Have Gotten Whacked. And That's OK
02:32pm, Friday, 13'th May 2022 The Motley Fool
It's all part of investing.
Why Cathie Wood's Flagship ETF Slumped This Week
08:19pm, Thursday, 12'th May 2022 The Motley Fool
The highly prominent investor's ETFs are suffering in the tech sell-off.
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for se
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
06:23pm, Tuesday, 10'th May 2022 Benzinga
RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and ha
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
02:32pm, Tuesday, 10'th May 2022
RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and ha
CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates
02:30pm, Tuesday, 10'th May 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.
CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates
12:03pm, Tuesday, 10'th May 2022
CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
09:15pm, Monday, 09'th May 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
06:49pm, Monday, 09'th May 2022
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
02:37pm, Friday, 06'th May 2022 Zacks Investment Research
Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
12:00pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for se
